Author(s)

Ayaka Saito^1,2, Takako Onuki², Yoshihisa Echida², Shigeru Otsubo³, Kosaku Nitta^1*

¹Department of Medicine, Kidney Center, Tokyo Women’s Medical University, Tokyo, Japan.
²Department of Medicine, Towa Hospital, Tokyo, Japan.
³Department of Blood Purification, Sangenjaya Hospital, Tokyo, Japan.

Background: Left ventricular hypertrophy (LVH) is a common cardiovascular complication and an independent risk factor for cardiovascular death in hemodialysis (HD) patients. Previous studies have shown that fibroblast growth factor 23 (FGF23), which has an important role in phosphate metabolism, is elevated in HD patients. Objectives: The aim of this study was to determine the association of FGF23 and LVH and the prognostic value of serum FGF23 level in HD patients. One hundred seven HD patients were evaluated for LVH by echocardiography. Serum FGF23 levels were measured using a commercial enzyme-linked immunosorbent assay kit. Results: Patients with LVH were more likely to have higher systolic blood pressure (BP) and LVH was significantly associated with female gender and higher serum levels of phosphate and calcium ×phosphate products. LVH was also associated with higher serum FGF23 level. Multivariate analysis indicated that serum FGF23 level, systolic BP, and serum phosphate level remained correlated with LVH. This suggested that serum FGF23 level is independently associated with LVH in our HD patients. Cox analysis indicated no significant difference in risk of death for patients with elevated serum FGF23 level. Conclusion: LVH has a high prevalence in HD patients, and FGF23 is independently associated with LVH but is not a predictor for prognosis during a 4-year follow-up period.

Fibroblast Growth Factor 23, Hemodialysis, Left Ventricular Hypertrophy, Prognosis

Saito, A. , Onuki, T. , Echida, Y. , Otsubo, S. and Nitta, K. (2014) Fibroblast Growth Factor 23 and Left Ventricular Hypertrophy in Hemodialysis Patients. International Journal of Clinical Medicine, 5, 1102-1110. doi: 10.4236/ijcm.2014.517141.